002589 瑞康医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.2230.3750.374-28.2241.745
总资产报酬率 ROA (%)0.0770.1260.116-8.1870.448
投入资产回报率 ROIC (%)0.0960.1610.149-11.0480.655

边际利润分析
销售毛利率 (%)11.54810.99910.29413.58218.229
营业利润率 (%)0.3060.321-1.576-13.9412.370
息税前利润/营业总收入 (%)1.9932.115-0.035-11.2214.409
净利润/营业总收入 (%)0.4990.5150.398-14.1231.814

收益指标分析
经营活动净收益/利润总额(%)-1,071.928-127.548152.26717.889109.154
价值变动净收益/利润总额(%)349.514305.181-132.86752.29744.804
营业外收支净额/利润总额(%)-263.63338.5776.4851.565-7.324

偿债能力分析
流动比率 (X)1.1111.1151.0721.0281.252
速动比率 (X)1.0371.0410.9680.9521.127
资产负债率 (%)64.41964.40466.26468.62763.279
带息债务/全部投入资本 (%)56.53656.19957.04062.53958.498
股东权益/带息债务 (%)76.14977.14274.63259.40469.589
股东权益/负债合计 (%)54.16853.71949.20242.98145.301
利息保障倍数 (X)1.0441.328-0.021-3.8152.003

营运能力分析
应收账款周转天数 (天)189.732172.360176.438210.502205.205
存货周转天数 (天)40.30347.06351.78751.13652.320